Dr. Lysinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2800 10th Ave N
Billings, MT 59101Phone+1 406-238-2500Fax+1 406-435-2278
Education & Training
University of ColoradoFellowship, Pediatric Pulmonology, 2005 - 2008- University of ColoradoResidency, Pediatrics, 2002 - 2005
University of Washington School of MedicineClass of 2002
Certifications & Licensure
MT State Medical License 2009 - 2027
WY State Medical License 2021 - 2025
CO State Medical License 2008 - 2011
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Pulmonology
Clinical Trials
- Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study Start of enrollment: 2023 Apr 23
Roles: Contact
Publications & Presentations
PubMed
- 3 citationsImpact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.Nicole Mayer-Hamblett, Alex H Gifford, Margaret Kloster, Renee Russell, Andrew T Braun
Annals of the American Thoracic Society. 2024-11-01 - 1 citationsReal-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.Thomas Keens, Veena Hoffman, Ia Topuria, Ken Elder, Shannon Cerf
Heliyon. 2024-04-15 - 2 citationsAirway inflammation accelerates pulmonary exacerbations in cystic fibrosis.Theodore G Liou, Natalia Argel, Fadi Asfour, Perry S Brown, Barbara A Chatfield
Iscience. 2024-03-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: